AB 423

Drug Profile

AB 423

Alternative Names: AB-423

Latest Information Update: 12 Apr 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Baruch S. Blumberg Institute; Drexel University College of Medicine
  • Developer Arbutus Biopharma
  • Class Antivirals; Bacteriophages; Small molecules
  • Mechanism of Action Capsid protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Hepatitis B

Most Recent Events

  • 04 May 2017 Arbutus Biopharma plans a phase II multiple ascending dose trial for Hepatitis B in the second half of 2017
  • 01 Jan 2017 Phase-I clinical trials in Hepatitis B (In healthy volunteers) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top